tiprankstipranks
Telomir Pharmaceuticals, Inc. (TELO)
NASDAQ:TELO
US Market
TELO
Telomir Pharmaceuticals, Inc.
RESEARCH TOOLSreports
Want to see TELO full AI Analyst Report?

Telomir Pharmaceuticals, Inc. (TELO) Income Statement

208 Followers

Telomir Pharmaceuticals, Inc. Income Statement

Last quarter (Q4 2025), Telomir Pharmaceuticals, Inc.'s total revenue was $0.00, a decrease of ― from the same quarter last year. In Q4, Telomir Pharmaceuticals, Inc.'s net income was $-2.06M. See Telomir Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Operating Expenses
$ 10.54M$ 12.24M$ 3.94M$ 854.15K$ 138.13K
Depreciation and Amortization
$ 0.00$ 12.24M$ 0.00$ 854.15K$ 138.13K
EBITDA
$ -10.54M$ 48.00K$ -11.43M$ 0.00$ 0.00
Operating Income
$ -10.54M$ -12.24M$ -3.94M$ -854.15K$ -138.13K
Other Income/Expenses
$ 125.64K$ -4.29M$ -9.13M$ 0.00$ 0.00
Pretax Income
$ -10.41M$ -16.53M$ -13.07M$ -854.15K$ -138.13K
Net Income
$ -10.41M$ -16.53M$ -13.07M$ -854.15K$ -138.13K
Per Share Metrics
Basic EPS
$ -0.33$ -0.56$ -0.44$ -0.03$ 0.00
Diluted EPS
$ -0.33$ -0.56$ -0.44$ -0.03$ 0.00
Weighted Average Shares Outstanding
 31.65M 29.54M 29.61M 29.61M 29.61M
Weighted Average Shares Outstanding (Diluted)
 31.65M 29.54M 29.61M 29.61M 29.61M
Currency in USD

Telomir Pharmaceuticals, Inc. Earnings and Revenue History